Teva Pharma (TEVA) Tops Q4 EPS by 2c, provides guidance

Teva Pharma (NYSE: TEVA) reported Q4 EPS of $0.71, $0.02 better than the analyst estimate of $0.69. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.1 billion.

GUIDANCE:

Teva Pharma sees FY2025 EPS of $2.35-$2.65, versus the consensus of $2.78. Teva Pharma sees FY2025 revenue of $16.8-17.4 billion, versus the consensus of $17.087 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• Barrick Mining said to delay IPO of American gold business to 2027
• Meta unveils Muse Spark 1.3 with coding improvements
• Evercore ISI: 'AAPL has so far offset softer App Store trends with faster-growing areas'